中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 9
Sep.  2020
Turn off MathJax
Article Contents

Measurement and clinical significance of peripheral blood vascular endothelial growth factor in patients with liver cirrhosis and portal vein thrombosis

DOI: 10.3969/j.issn.1001-5256.2020.09.011
Research funding:

 

  • Received Date: 2020-03-11
  • Published Date: 2020-09-20
  • Objective To investigate the level of vascular endothelial growth factor( VEGF) in the peripheral blood of patients with liver cirrhosis and portal vein thrombosis( PVT) and its clinical significance in the diagnosis of liver cirrhosis with PVT. Methods A total of 60 patients with liver cirrhosis and PVT who were followed up or hospitalized in the outpatient service of The First Affiliated Hospital of Soochow University from January 2017 to December 2019 were enrolled as PVT group,and 161 patients with liver cirrhosis and portal hypertension who had no thrombi were enrolled as LC group. Related clinical data were collected,including sex,age,white blood cell count,platelet count,total bilirubin,alanine aminotransferase,albumin,prothrombin time,international normalized ratio,and antithrombin Ⅲ. Double-antibody sandwich ELISA was used to measure the serum level of VEGF. The t-test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Pearson correlation test was used for correlation analysis,and a binary logistic regression analysis was used to investigate the risk factors for PVT in patients with liver cirrhosis.Results The comparison of baseline indices showed that there was a significant difference in serum VEGF between the PVT group and the LC group( P < 0. 05). The comparison of the patients with Child-Pugh class A,B or C disease showed that there was a significant difference in serum VEGF between the two groups( Z = 3. 749,5. 469,all P < 0. 05). The stepwise logistic regression analysis showed that only serum VEGF( odds ratio = 1. 004,95% confidence interval: 1. 003-1. 006,P < 0. 001) was an independent risk factor for liver cirrhosis with PVT. Conclusion Patients with liver cirrhosis and PVT tend to have a high level of VEGF in peripheral blood,which provides guidance for clinical diagnosis.

     

  • loading
  • [1] TSOCHATZIS EA,SENZOLO M,GERMANI G,et al. Systematic review:Portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther,2010,31(3):366-374.
    [2] RIBEIRO OD,CANEDO NHS,PANNAIN VL. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis:Correlation with pathological features[J]. Clinics(Sao Paulo),2016,71(11):639-643.
    [3] KIM HO,KIM SK,SON BH,et al. Intraoperative radiofrequency ablation with or without tumorectomy for hepatocellular carcinoma in locations difficult for a percutaneous approach[J].Hepatobiliary Pancreat Dis Int,2009,8(6):591-596.
    [4] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
    [5] TRIPODI A. Hemostasis in acute and chronic liver disease[J]. Semin Liver Dis,2017,37(1):28-32.
    [6] RATNASARI N,NURDJANAH S,SADEWA AH,et al. Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population[J]. PLo S One,2017,12(8):e0183503.
    [7] GADELHAK NA,GADELHAK SA,EL-MORSI DA,et al.Prognostic significance of three hepatitis markers(p53 antibodies,vascular endothelial growth factors and alpha fetoprotein)in patients with hepatocellular carcinoma[J]. Hepatogastroenterology,2009,56(94-95):1417-1424.
    [8] CHO HC,KIM JH,CHA RR,et al. Clinical significance of endothelial progenitor cells in patients with liver cirrhosis with or without hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol,2020,32(1):87-94.
    [9] ZELLER M,KORANDJI C,GUILLAND JC,et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction[J]. Arterioscler Thromb Vasc Biol,2008,28(5):954-960.
    [10] KIM TY,LEE JG,SOHN JH,et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis[J]. Yonsei Med J,2016,57(1):138-145.
    [11] SIEGHART W,FELLNER S,REIBERGER T,et al. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma[J]. Dig Liver Dis,2009,41(12):902-906.
    [12] LI CP,LEE FY,HWANG SJ,et al. Spider angiomas in patients with liver cirrhosis:Role of vascular endothelial growth factor and basic fibroblast growth factor[J]. World J Gastroenterol,2003,9(12):2832-2835.
    [13] SAMOTO K,IKEZAKI K,ONO M,et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors[J]. Cancer Res,1995,55(5):1189-1193.
    [14] DINKOVA-KOSTOVA AT,HOLTZCLAW WD,COLE RN,et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants[J]. Proc Natl Acad Sci U S A,2002,99(18):11908-11913.
    [15] FERRARA N,GERBER HP,LECOUTER J. The biology of VEGF and its receptors[J]. Nat Med,2003,9(6):669-676.
    [16] GELFAND MV,HAGAN N,TATA A,et al. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding[J]. Elife,2014,3:e03720.
    [17] SHWEIKI D,ITIN A,SOFFER D,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis[J]. Nature,1992,359(6398):843-845.
    [18] HOEBEN A,LANDUYT B,HIGHLEY MS,et al. Vascular endothelial growth factor and angiogenesis[J]. Pharmacol Rev,2004,56(4):549-580.
    [19] TOSON EA,SHIHA GE,ABDELGALEEL AE. Fibrogenic/angiogenic linker for non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C among egyptian patients[J].Ann Hepatol,2017,16(6):862-873.
    [20] LI L. Risk factors of portal vein thrombosis in cirrhotic patients from the view of Virchow’s triad[J]. J Prac Hepatol,2015,18(3):325-328.(in Chinese)李玲.从Virchow三要素分析肝硬化患者发生门静脉血栓危险因素[J].实用肝脏病杂志,2015,18(3):325-328.
    [21] Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin:Pulmonary Embolism Prevention(PEP)trial[J]. Lancet,2000,355(9212):1295-1302.
    [22] BASILI S,RAPARELLI V,VIOLI F. The coagulopathy of chronic liver disease[J]. N Engl J Med,2011,365(2):147-156.
    [23] ZOCCO MA,di STASIO E,de CRISTOFARO R,et al. Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol,2009,51(4):682-689.
    [24] FEYS HB,CANCIANI MT,PEYVANDI F,et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis[J]. Br J Haematol,2007,138(4):534-540.
    [25] NASIM M,MAJID B,TAHIR F,et al. Cavernous transformation of portal vein in the setting of protein C and anti-thrombin III deficiency[J]. Cureus,2019,11(9):e5779.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1188) PDF downloads(120) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return